Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.703
-0.017 (-2.29%)
At close: Nov 4, 2024, 4:00 PM
0.705
+0.002 (0.26%)
After-hours: Nov 4, 2024, 4:47 PM EST
Company Description
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus.
It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.
The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Cosmos Health Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Dec 13, 2013 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Grigorios Siokas |
Contact Details
Address: 141 West Jackson Boulevard, Suite 4236 Chicago, Illinois 60604 United States | |
| Phone | 312 536 3102 |
| Website | cosmosholdingsinc.com |
Stock Details
| Ticker Symbol | COSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001474167 |
| CUSIP Number | 221413206 |
| ISIN Number | US2214133058 |
| Employer ID | 27-0611758 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Grigorios Siokas | Chairman and Chief Executive Officer |
| Georgios Terzis | Chief Financial Officer |
| Nikolaos Bardakis | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 28, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 18, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 8, 2024 | PRER14A | Filing |
| Oct 1, 2024 | PRE 14A | Other preliminary proxy statements |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 17, 2024 | 424B3 | Prospectus |
| Sep 17, 2024 | 424B3 | Prospectus |
| Sep 17, 2024 | 424B3 | Prospectus |
| Sep 17, 2024 | 424B3 | Prospectus |